Recent Updates
Recently added Catalysts

Antidepressant+ SPD489

Phase 3

Major Depressive Disorder | Small molecule | Psychiatry |Takeda Pharmaceutical Company Limited|Last Updated: Jun 14, 2021

Success Probability

Subscribe to view

Market & Valuation

Subscribe to view

Trial Design

RandomizedDouble-BlindPLACEBO_CONTROLLED
Total Trials3
Total Enrollment2,548

FDA Designations

No designations recorded

Clinical trial landscape

Antidepressant+ SPD489 · 3 trials · 1 indication

Phase 3 1Phase 2 2
NCT01436162Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive DisorderMajor Depressive Disorder
COMPLETED1,105 Analytics
PHASE3COMPLETED
Efficacy and Safety Study of SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
Major Depressive DisorderUnlock trial analytics

Study Endpoints

Primary Endpoints

Mean Change From Baseline in Montgomery-Asberg Depression Rating Scale (MADRS) Total Score at 8 Weeks
8 weeks

MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression.

Change in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Total Score From Augmentation Baseline (Week 8) to Week 16 (Double-blind Phase, Dose Response Evaluable Set)
Augmentation Baseline (Week 8) to Week 16

MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression. CHange in MADRS total score in Augmentsion Baseline to Week 16.

Change From Augmentation Baseline for Non-Remitters in Montgomery-Ǻsberg Depression Rating Scale (MADRS) Total Score at Week 6 - Last Observation Carried Forward (LOCF)
Augmentation Baseline, 6 weeks

MADRS is a validated, 10-item rating scale with each item being scored on a scale from 0-6 with a total score ranging from 0-60. Lower scores indicate a decreased severity of depression.

Secondary Endpoints

Mean Change From Baseline in Sheehan Disability Scale (SDS) Total Score at 8 Weeks
8 weeks
Percentage of Participants Achieving a 25% Response on the MADRS
Up to 8 weeks
Percentage of Participants Achieving a 50% Response on the MADRS
Up to 8 weeks
Unlock Study Endpoints

Study Design & Arms

AllocationRANDOMIZED
MaskingQUADRUPLE
ModelPARALLEL
PurposeTREATMENT

Treatment Arms

ArmTypeDescription
Antidepressant + SPD489EXPERIMENTAL -
Antidepressant + PlaceboPLACEBO_COMPARATOR -
Antidepressant + SPD489 10 mgEXPERIMENTAL -
Antidepressant + SPD489 30 mgEXPERIMENTAL -
Antidepressant + SPD489 50 mgEXPERIMENTAL -
Antidepressant + SPD489 70 mgEXPERIMENTAL -
ActiveEXPERIMENTALAntidepressant + SPD489
PlaceboPLACEBO_COMPARATORAntidepressant + placebo

Interventions

NameTypeDescription
Antidepressant + SPD489 (Lisdexamfetamine dimesylate )DRUGAntidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + SPD489 (oral, 20, 30, 50 or 70 mg, once daily) for 8 weeks
Antidepressant + PlaceboDRUGAntidepressant (either escitalopram oxalate, sertraline hydrochloride, venlafaxine hydrochloride extended release or duloxetine hydrochloride) oral, once daily + Placebo (oral, once daily) for 8 weeks
Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 10 mgDRUGAntidepressant + SPD489 oral, 10 mg, once daily for 8 weeks
Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 30 mgDRUGAntidepressant + SPD489 oral, 30 mg, once daily for 8 weeks
Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 50 mgDRUGAntidepressant + SPD489 oral, 50 mg, once daily for 8 weeks
Antidepressant + SPD489 (Lisdexamfetamine dimesylate) 70 mgDRUGAntidepressant + SPD489 oral, 70 mg, once daily for 8 weeks
Antidepressant + SPD489 (lisdexamfetamine dimesylate)DRUGEscitalopram oxalate (antidepressant) 20 mg/day oral + 20, 30, or 50 mg SPD489 oral once daily for 6 weeks
Unlock Study Design Details

Eligibility Criteria

Age Range18 Years to 65 Years
SexALL
Healthy VolunteersNo
Study Sites101

Inclusion Criteria 1. Subject is able to provide written, personally signed, and dated informed consent to participate in the study before completing any study-related procedures. 2. Subject is between 18 and 65 years of age. 3. Subject has a primary diagnosis of non-psychotic MDD. 4. Subject has a...

Countries:United StatesBelgiumCzechiaEstoniaFinlandGermanyHungaryPolandRomaniaSouth AfricaSwedenArgentinaAustraliaChileUnited Kingdom
Unlock Eligibility Criteria